Jim Cramer on Regeneron: “They’re Doing a Lot of Good Stuff, I Lost Sight of It, I Shouldn’t Have”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer was recently asked about. A caller asked if the stock, up 54% from its “summer lows”, can continue its momentum. Here’s what Mad Money’s host had to say in response:

“Yes, down 30 today… Well, it’s a $750 stock. Now, let me just tell you something. Regeneron’s move has been quiet, but Len Schleifer has been telling me, stay focused on what they’re doing. They’re doing a lot of good stuff. I lost sight of it. I shouldn’t have. This one and Amgen bother me. They happened without me, and that was my bad, and I’m glad you brought it to our attention.”

Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. During the November 20 episode, a caller inquired about the stock, and Cramer responded:

“I should have been recommending Regeneron. That Len Schleifer pulled the rabbit out of a hat. It’s coming right back right now. By the way, I’ll give you a twofer, so is Amgen.”

While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.